Cipla’s Bengaluru manufacturing facility classified as VAI by USFDA

05 Aug 2025 Evaluate

United States Food and Drug Administration (USFDA) has classified current Good Manufacturing Practices (cGMP) inspection conducted at Cipla’s manufacturing facility located in Bommasandra, Bengaluru as Voluntary Action Indicated (VAI). USFDA had conducted the inspection at said facility from May 26 to May 30, 2025.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1505.05 8.70 (0.58%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×